Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents

Huang, Li-Min; Chang, Luan-Yin; Tang, Haiwen; Bock, Hans L.; Lu, Chun-Yi; Huang, Fu-Yuan; Lin, Tzou-Yien; Lee, Chin-Yun

doi:10.1016/j.jadohealth.2005.08.009

« Previous Next »Journal of Adolescent Health
Volume 37, Issue 6 , Pages 517.e1-517.e5, December 2005

Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents

Li-Min Huang, MD, PhD
- Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
Luan-Yin Chang, MD, PhD
- Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
Haiwen Tang, MD, PhD
- GlaxoSmithKline Biologicals, Rixensart, Belgium
Hans L. Bock, MD
- GlaxoSmithKline Biologicals, Rixensart, Belgium
Chun-Yi Lu, MD
- Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
Fu-Yuan Huang, MD
- Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
Tzou-Yien Lin, MD
- Chang Gung Children’s Hospital and Chang Gung University, College of Medicine, Taoyuan, Taiwan
- Address correspondence to: Dr. Tzou-Yien Lin, Chang Gung Children’s Hospital, No. 5, Fu-shin St, Kweishang, Taipei, Taiwan.
Chin-Yun Lee, MD
- Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

Received 3 May 2005; accepted 10 August 2005.

Abstract

Purpose

Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals’ reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine.

Methods

Healthy Taiwanese children and adolescents aged 6–8 years and 15–20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded.

Results

A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0–100%. There were no serious adverse events reported during the study period.

Conclusions

The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.

Keywords: Reduced-antigen-content dTpa vaccine , Bordetella pertussis , Taiwan , Booster vaccination , Adolescents